Radius Health Inc (RDUS) Position Lifted by Bank of Montreal Can

Bank of Montreal Can lifted its position in shares of Radius Health Inc (NASDAQ:RDUS) by 4,385.9% during the first quarter, HoldingsChannel reports. The firm owned 69,262 shares of the biopharmaceutical company’s stock after acquiring an additional 67,718 shares during the period. Bank of Montreal Can’s holdings in Radius Health were worth $1,382,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System lifted its position in shares of Radius Health by 2.9% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 23,460 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 656 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Radius Health by 9.4% during the fourth quarter. Legal & General Group Plc now owns 17,227 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 1,478 shares in the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Radius Health by 56.4% during the third quarter. MetLife Investment Advisors LLC now owns 27,474 shares of the biopharmaceutical company’s stock valued at $489,000 after purchasing an additional 9,912 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Radius Health by 395.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,549 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 10,812 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Radius Health during the fourth quarter valued at about $205,000.

A number of research firms recently weighed in on RDUS. HC Wainwright reissued a “hold” rating on shares of Radius Health in a research report on Thursday, May 9th. Cowen reissued a “hold” rating on shares of Radius Health in a research report on Wednesday, May 8th. Zacks Investment Research raised shares of Radius Health from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Monday, May 6th. BidaskClub lowered shares of Radius Health from a “buy” rating to a “hold” rating in a research report on Tuesday, April 23rd. Finally, ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $38.00.

Shares of RDUS stock opened at $20.79 on Wednesday. The stock has a market capitalization of $958.57 million, a price-to-earnings ratio of -4.26 and a beta of 0.98. The company has a debt-to-equity ratio of 6.75, a quick ratio of 5.04 and a current ratio of 5.16. Radius Health Inc has a 52 week low of $12.81 and a 52 week high of $31.92.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. The business had revenue of $34.42 million for the quarter, compared to analyst estimates of $33.99 million. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. Research analysts predict that Radius Health Inc will post -3.51 earnings per share for the current year.

In other Radius Health news, Director Willard H. Dere sold 1,680 shares of Radius Health stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $22.22, for a total value of $37,329.60. Following the sale, the director now owns 8,620 shares of the company’s stock, valued at $191,536.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jessica Hopfield acquired 12,800 shares of the stock in a transaction on Tuesday, March 5th. The stock was bought at an average cost of $19.23 per share, for a total transaction of $246,144.00. Following the transaction, the director now owns 12,800 shares of the company’s stock, valued at approximately $246,144. The disclosure for this purchase can be found here. Insiders own 4.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by WKRB News and is owned by of WKRB News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.wkrb13.com/2019/05/22/radius-health-inc-rdus-position-lifted-by-bank-of-montreal-can.html.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

See Also: What is the Stochastic Momentum Index (SMI)?

Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.